{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"retatrutide","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/retatrutide/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"retatrutide","title":"Retatrutide","register":"essay","tags":["peptide","retatrutide","glp-1","obesity","disc"],"updated_at":"2026-07-24T17:41:58.775Z","body_excerpt":"Retatrutide is an investigational once-weekly injection from Eli Lilly that hits three hormone receptors at once — GLP-1, GIP, and glucagon. In its Phase 2 obesity trial the top dose produced a 24.2% average weight loss at 48 weeks, the largest ever reported for a drug alone, and the curve had not flattened. It is the newest and strongest member of the incretin class, it is not approved or for sale anywhere yet, and it keeps appearing in conversations about spinal discs for one concrete reason: body weight is a load a disc has to carry, and Lilly is already trialing this drug for knee osteoarthritis, sleep apnea, and — directly relevant — chronic low back pain. This page is the full picture: the three-receptor mechanism, the exact efficacy and dosing, the adverse events with real numbers, the striking liver-fat data, how it compares to semaglutide and tirzepatide, the muscle-loss question, and the honest version of the spine argument. Zero prior knowledge assumed.\n\n## Three receptors, one bet\n\nTirzepatide already showed what happens when you agonize GLP-1 and GIP together: appetite falls, the stomach empties slower, people eat less. Retatrutide adds the glucagon receptor, which does the opposite of what a diabetes-adjacent drug \"should\" — it raises energy expenditure and pushes the liver to burn fat. So the molecule works both ends at once: less energy in, more energy out, from one weekly shot. A 2025 review called it, without much hedging, a game-changer in obesity pharmacotherapy.\n\n[[embed:source:s5]]\n\nThe glucagon arm is also the double-edged part. It is what makes retatrutide potentially stronger on fat loss, and it is the receptor that most demands the careful Phase 3 safety read — glucagon nudges heart rate and glucose output — which is part of why the program is so large.\n\n## The number that got everyone's attention\n\nThe Phase 2 obesity trial ran 48 weeks. Least-squares mean weight change by dose: −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% at 12 mg. At that top dose, everyone lost at least 5%, 93% lost ≥10%, 83% lost ≥15%, about half lost ≥25%, and a quarter lost ≥30%. Critically, the trajectory had not plateaued at 48 weeks — implying more loss with longer treatment, which Phase 3 later bore out (~28% at 80 weeks).\n\n[[embed:source:s4]]\n\nIt is disproportionately fat, too: a body-composition substudy in type 2 diabetes found retatrutide cut total fat mass more than both placebo and dulaglutide.\n\n[[embed:source:s6]]\n\n## The liver result is the quiet headline\n\nThe effect on liver fat is arguably more striking than the scale number. In the Phase 2a MASLD substudy, relative liver-fat reduction at 48 weeks reached −86.0% at 12 mg, and 93% of those patients dropped to a normal liver-fat level (under 5%) versus zero on placebo. Hepatologists called it among the most potent pharmacologic liver-fat reductions ever reported — credited to the glucagon arm — and it drove a dedicated Phase 3 MASH program with biopsy endpoints.\n\n## How it's dosed, and why the ramp is slow\n\nRetatrutide is a subcutaneous injection once weekly (half-life ~6 days). Dosing is titrated up over months: start at 2 or 4 mg, escalate every four weeks. That slow ramp is not marketing — the adverse events cluster during escalation, and a lower 2 mg start measurably reduced them. Going too fast is how people get the GI effects that make them quit.\n\n## The adverse events, with real numbers\n\nThe profile is the incretin-class one, dose-dependent, mostly during escalation. At 12 mg: nausea 45%, decreased appetite 29%, vomiting 19%, constipation 16%, diarrhea 15%, fatigue 10% (placebo nausea was 11%). Discontinuation for adverse events ran 6-16% versus 0% on placebo. Two glucagon-specific notes: heart rate rose dose-dependently, peaking around week 24 then declining, and despite glucagon's tendency to raise blood sugar there was no clinically significant hypoglycemia — glycemic control actually improved, with 72% of prediabetic participants returning to nor","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"rc-safety","text":"Adverse events are the dose-dependent incretin profile — nausea, diarrhea, vomiting; a safety review found the profile acceptable but did not establish long-term safety.","tier":"human","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s2","s4"],"why_material":"Names the known harms and their dependence on dose.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"rc-phase3","text":"The Phase 3 TRIUMPH program is ongoing and retatrutide is not approved by any regulator as of writing; everything here is investigational trial data.","tier":"system","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s8","s7"],"why_material":"Bounds the evidence — no approval, no completed Phase 3.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"rc-ruo","text":"This is a research-use-only compound. The article reports trial data; it is not medical advice and does not establish a treatment for any person.","tier":"system","slot":"limitations","interaction_risk":false,"status":"active","source_ids":[],"why_material":"Compliance and reader-safety boundary.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"rc-obesity","text":"In adults with obesity, meta-analysis finds retatrutide produces large, dose-dependent body-weight reductions, statistically and clinically superior to placebo, with the highest doses approaching ~24% at ~48 weeks.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s3","s4"],"why_material":"The headline efficacy claim, graded to pooled human data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"rc-t2d","text":"In type 2 diabetes, a Phase 2 substudy found retatrutide significantly improved total body-fat-mass reduction versus both placebo and dulaglutide.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s6"],"why_material":"Efficacy beyond obesity, in a controlled comparison.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"rc-mech","text":"Retatrutide is a single synthetic peptide that agonizes three receptors at once — GLP-1, GIP, and glucagon (GCGR).","tier":"mechanistic","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s8"],"why_material":"Defines what the compound is and why it differs from dual agonists.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"rc-mech2","text":"Glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation, adding an energy-output arm on top of the appetite-suppressing GLP-1/GIP arms.","tier":"mechanistic","interaction_risk":false,"status":"active","source_ids":["s5"],"why_material":"Explains the mechanistic rationale for the third receptor.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","summary":"2026 Lancet phase 3 trial (TRANSCEND-T2D-1) on retatrutide efficacy/safety in T2D patients.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"df8055142eadabf7d24e2f23e04866ae06fcff7b1651d65d2b383de14f67ebd8"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","title":"Efficacy and safety of retatrutide for the treatment of obesity","quote":"This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.","summary":"2025 systematic review on retatrutide safety/efficacy for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"c967d92d24a7584a0661998f5f859935393e31e887b1fcd49302bfcc28a63120"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.","summary":"2025 meta-analysis showing retatrutide superior to placebo for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"5b897b8c865f133b1ccb2b3ca4ad5552a703054ae8df4d0e5e2b2f352289ea6b"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"2025 meta-analysis on retatrutide for obesity treatment.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"894a8378b761e3dbe9712cf88f12b43698950a6fc5eb1c75379bfdb457e3e9e6"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.","summary":"2025 review on retatrutide mechanisms, efficacy, and safety.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"beaa8c68dae730464fd3282304a7f9e27396f03351c3ae690b82e2abee1becfb"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"2025 phase 2 substudy on retatrutide effects on body composition in T2D.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"6986319f262946376b00ea616b8614d5089e29289a6362c38691ba7afdcfed39"},{"id":"s7","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.","summary":"Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"397ba2c51b294d919cc41ed0526b427a3dac07b01cb0fdf95602412edc398d38"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease states.","summary":"Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"3f0458a22c0cf3b2f3f02893a8c6f364b998f87d37bb478093f479ff12e1bd9e"},{"id":"s9","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"3ed1814e3170f9d2ceb83059fefc0fcccf9b1edf6949d420edc241395739d23b"},{"id":"s10","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"5991724bd0539547aa4d742cd634247033cb5129d0dbbbf24190715859e2711c"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","summary":"2026 Lancet phase 3 trial (TRANSCEND-T2D-1) on retatrutide efficacy/safety in T2D patients.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"df8055142eadabf7d24e2f23e04866ae06fcff7b1651d65d2b383de14f67ebd8"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","title":"Efficacy and safety of retatrutide for the treatment of obesity","quote":"This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.","summary":"2025 systematic review on retatrutide safety/efficacy for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"c967d92d24a7584a0661998f5f859935393e31e887b1fcd49302bfcc28a63120"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.","summary":"2025 meta-analysis showing retatrutide superior to placebo for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"5b897b8c865f133b1ccb2b3ca4ad5552a703054ae8df4d0e5e2b2f352289ea6b"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"2025 meta-analysis on retatrutide for obesity treatment.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"894a8378b761e3dbe9712cf88f12b43698950a6fc5eb1c75379bfdb457e3e9e6"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.","summary":"2025 review on retatrutide mechanisms, efficacy, and safety.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"beaa8c68dae730464fd3282304a7f9e27396f03351c3ae690b82e2abee1becfb"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"2025 phase 2 substudy on retatrutide effects on body composition in T2D.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"6986319f262946376b00ea616b8614d5089e29289a6362c38691ba7afdcfed39"},{"id":"s7","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.","summary":"Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"397ba2c51b294d919cc41ed0526b427a3dac07b01cb0fdf95602412edc398d38"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease states.","summary":"Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"3f0458a22c0cf3b2f3f02893a8c6f364b998f87d37bb478093f479ff12e1bd9e"},{"id":"s9","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"3ed1814e3170f9d2ceb83059fefc0fcccf9b1edf6949d420edc241395739d23b"},{"id":"s10","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"5991724bd0539547aa4d742cd634247033cb5129d0dbbbf24190715859e2711c"}],"user_reports":[],"related_articles":[{"slug":"the-disc-stack","title":"The Disc Recovery Stack","claims":[{"id":"c1","text":"The disc is the body's largest avascular structure and repairs poorly on its own, which is the central obstacle any disc-recovery strategy must overcome.","tier":"mechanistic"},{"id":"c2","text":"The body already removes most herniations: ~67% resorb spontaneously via a macrophage- and blood-vessel-driven process, so recovery means supporting an existing mechanism, not forcing a new one.","tier":"human"},{"id":"c3","text":"Body weight is a modifiable driver: overweight and obesity raise the odds of sciatica and disc herniation, making load reduction the one lever a person directly controls.","tier":"human"},{"id":"c4","text":"TNF-alpha and IL-1beta drive both disc degeneration and the inflammatory nerve pain of a herniation, making the inflammatory signal a shared target.","tier":"mechanistic"},{"id":"c5","text":"A human meta-analysis found stem-cell injection may reduce discogenic pain and disability, the first real human signal that the disc is a regeneration target - though still small and early.","tier":"human"}]},{"slug":"bpc-157","title":"BPC-157: Body Protection Compound","claims":[{"id":"c1","text":"BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.","tier":"human"},{"id":"c2","text":"Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.","tier":"preclinical"},{"id":"c3","text":"A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.","tier":"human"},{"id":"c4","text":"Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.","tier":"mechanistic"},{"id":"c5","text":"One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).","tier":"anecdotal"},{"id":"c6","text":"One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).","tier":"anecdotal"},{"id":"c7","text":"One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).","tier":"anecdotal"},{"id":"c8","text":"One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).","tier":"anecdotal"}]},{"slug":"tb-500","title":"TB-500 (Thymosin Beta-4)","claims":[{"id":"c1","text":"TB-500 is a synthetic version of thymosin beta-4, the body's principal G-actin-sequestering peptide, which regulates the actin dynamics that govern cell migration — the molecular basis for its role in tissue repair.","tier":"mechanistic"},{"id":"c2","text":"The same seven-amino-acid actin-binding motif that gives Tb4 its structural function also drives angiogenesis and endothelial migration, so new blood-vessel growth is intrinsic to how it repairs tissue.","tier":"mechanistic"},{"id":"c3","text":"In controlled animal wound models, Tb4 accelerated skin regeneration (reepithelialization up 42-61%) while increasing collagen deposition and angiogenesis.","tier":"preclinical"},{"id":"c4","text":"Tb4 reached genuine randomized, double-blind, placebo-controlled human trials for chronic wounds (pressure and venous stasis ulcers), where it was safe but did not hit statistical significance on primary healing endpoints.","tier":"human"},{"id":"c5","text":"The ophthalmic Tb4 formulation RGN-259 showed positive Phase II human efficacy for dry-eye signs and symptoms via corneal epithelial repair — the strongest controlled human efficacy signal for the peptide.","tier":"human"},{"id":"c6","text":"In preclinical cardiac injury, both local and systemic Tb4 dosing reduced infarct size and improved function via cardiomyocyte survival (ILK/Akt) and angiogenesis.","tier":"preclinical"},{"id":"c7","text":"Tb4 improved ligament healing histologically and mechanically in a rat MCL model, but a 2026 scoping review confirms tendon, ligament, muscle and spine/disc evidence remains overwhelmingly animal-stage with no confirmatory human musculoskeletal trials.","tier":"preclinical"},{"id":"c8","text":"Across multiple chronic human wound types Tb4 has been reported to promote faster repair, extending its regenerative case into diseased human tissue.","tier":"human"}]},{"slug":"ara-290","title":"ARA-290 (Cibinetide)","claims":[{"id":"c1","text":"ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.","tier":"mechanistic"},{"id":"c2","text":"Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding EPO's thrombotic risk.","tier":"mechanistic"},{"id":"c3","text":"The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.","tier":"mechanistic"},{"id":"c4","text":"In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom scores versus placebo.","tier":"human"},{"id":"c5","text":"In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an objective structural sign of nerve regeneration.","tier":"human"},{"id":"c6","text":"In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.","tier":"human"},{"id":"c7","text":"In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory response.","tier":"preclinical"},{"id":"c8","text":"ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.","tier":"preclinical"}]},{"slug":"degenerative-disc-disease","title":"Degenerative Disc Disease","claims":[{"id":"c1","text":"Degeneration begins as a molecular failure of hydration: the nucleus pulposus loses aggrecan and water (from ~90% water at birth to ~70% by age 60), so it can no longer pressurize and share load.","tier":"mechanistic"},{"id":"c2","text":"The disc heals poorly because it is the body's largest avascular structure, fed only by slow diffusion through the vertebral endplates.","tier":"mechanistic"},{"id":"c3","text":"Once the nucleus dehydrates, load transfers to the annulus fibrosus, which fissures and tears; the injury response is outpaced by ongoing degeneration.","tier":"mechanistic"},{"id":"c4","text":"TNF-alpha and IL-1beta are the key inflammatory mediators of disc degeneration and discogenic pain, produced by the disc cells themselves, and they drive nerve ingrowth into the normally aneural disc.","tier":"mechanistic"},{"id":"c5","text":"In a controlled rat model, injecting TNF-alpha caused both pain and degeneration while blocking it at the time of injury prevented them, showing TNF-alpha is a causal driver, not just a marker.","tier":"preclinical"},{"id":"c6","text":"TNF-alpha shifts the disc's matrix economy toward breakdown by raising matrix-degrading MMPs relative to their inhibitors (TIMPs), so catabolism outpaces the anabolism that would rebuild the disc.","tier":"mechanistic"},{"id":"c7","text":"Higher adiposity and abdominal obesity are associated with more severe lumbar disc degeneration on MRI, even in young adults, making body weight a modifiable risk factor.","tier":"human"},{"id":"c8","text":"The 'one pound of body weight equals about four pounds on the lumbar spine' figure is not a validated bodyweight-scaling law; the real ~4-5x load increases measured inside living discs come from forward flexion and lifting (relaxed standing ~0.5 MPa vs lifting 20 kg with a rounded back ~2.3 MPa), i.e. posture and lever-arm.","tier":"human"}]}],"question_graph":{"slug":"retatrutide","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":7,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":7,"claims_total":7,"sources":10,"anecdotal":0,"scientific":10,"user_reports":0,"questions":0,"evidence_ingests":0}}